Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts

Ryan C. Ungaro(Feinstein Institute for Medical Research), Tine Jess(NOAA National Centers for Environmental Prediction)

Gut

November 12, 2018

10.1136/gutjnl-2018-317021

Cited by 65

Related Papers

Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy

|Cell|2019|902

Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

|Gastroenterology|2020|692

Neonatal vitamin D status and risk of multiple sclerosis

|Neurology|2016|135

Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2–related Disease

|Gastroenterology|2020|131

Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets

|Gastroenterology|2021|87